BEGIN:VCALENDAR

VERSION:2.0

PRODID:-//wp-events-plugin.com//7.2.2.1//EN

TZID:Asia/Jerusalem

X-WR-TIMEZONE:Asia/Jerusalem
BEGIN:VEVENT

UID:1355@biology.technion.ac.il

DTSTART;TZID=Asia/Jerusalem:20260309T130000

DTEND;TZID=Asia/Jerusalem:20260309T140000

DTSTAMP:20260304T131508Z

URL:https://biology.technion.ac.il/en/seminars/phd-graduate-seminar-almog-
 angel/

SUMMARY:PhD Graduate Seminar-Almog Angel [No Categories]
DESCRIPTION:Location:  Hybrid - in the Faculty Auditorium /ZOOM: https://te
 chnion.zoom.us/j/91997034360  \n Affiliation: Almog Angel\n Host:Dr. Dvir 
 Aran\n Computational Characterization of the Tumor Microenvironment for Op
 timizing Immunotherapy Response\n\nImmunotherapy has transformed cancer tr
 eatment\, yet most patients do not achieve a durable benefit. A prevailing
  hypothesis is that differences in the tumor microenvironment (TME) influe
 nce therapeutic response\, highlighting the need for accurate tools to cha
 racterize tumor cellular composition. In the first part of my PhD\, I deve
 loped xCell 2.0\, an improved computational method for inferring cell type
  enrichment from bulk transcriptomic data. The framework introduces a flex
 ible training pipeline and automated handling of cell type dependencies\, 
 enabling robust performance across diverse reference datasets. In extensiv
 e benchmarking across human and mouse datasets\, xCell 2.0 outperformed ex
 isting deconvolution methods and improved prediction of immunotherapy resp
 onse in pan-cancer analyses. In the second part\, I investigated how chemo
 therapy may reshape the TME to influence response to subsequent immunother
 apy. I derived a transcriptomic signature that identifies tumors likely to
  undergo favorable immune remodeling following chemotherapy. Notably\, thi
 s benefit is specific to patients receiving combined chemo-immunotherapy a
 nd not immunotherapy alone\, consistent with a model of chemotherapy-media
 ted immune priming. Together\, this work provides both a methodological ad
 vance for TME characterization and a mechanism-informed framework for iden
 tifying patients who may benefit from combined or sequential chemo-immunot
 herapy strategies.\n\n&nbsp\; 
LOCATION: Hybrid - in the Faculty Auditorium /ZOOM: https://technion.zoom.u
 s/j/91997034360

END:VEVENT

BEGIN:VTIMEZONE

TZID:Asia/Jerusalem

X-LIC-LOCATION:Asia/Jerusalem

BEGIN:STANDARD

DTSTART:20251026T010000

TZOFFSETFROM:+0300

TZOFFSETTO:+0200

TZNAME:IST

END:STANDARD

END:VTIMEZONE
END:VCALENDAR